133 related articles for article (PubMed ID: 24681933)
1. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Iida S; Ri M
Rinsho Ketsueki; 2014 Mar; 55(3):304-10. PubMed ID: 24681933
[No Abstract] [Full Text] [Related]
2. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Shuqing L; Jianmin Y; Chongmei H; Hui C; Wang J
Exp Hematol; 2011 Dec; 39(12):1117-8. PubMed ID: 21920470
[No Abstract] [Full Text] [Related]
3. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
4. FDA approves new agent for multiple myeloma.
Fenichel MP
J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612
[No Abstract] [Full Text] [Related]
5. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Zhu YX; Tiedemann R; Shi CX; Yin H; Schmidt JE; Bruins LA; Keats JJ; Braggio E; Sereduk C; Mousses S; Stewart AK
Blood; 2011 Apr; 117(14):3847-57. PubMed ID: 21289309
[TBL] [Abstract][Full Text] [Related]
6. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
7. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
8. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
9. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Orlowski RZ
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Shaughnessy JD; Qu P; Usmani S; Heuck CJ; Zhang Q; Zhou Y; Tian E; Hanamura I; van Rhee F; Anaissie E; Epstein J; Nair B; Stephens O; Williams R; Waheed S; Alsayed Y; Crowley J; Barlogie B
Blood; 2011 Sep; 118(13):3512-24. PubMed ID: 21628408
[TBL] [Abstract][Full Text] [Related]
13. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC
J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544
[TBL] [Abstract][Full Text] [Related]
15. Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Gu JL; Li J; Zhou ZH; Liu JR; Huang BH; Zheng D; Su C
Biochem Biophys Res Commun; 2012 Apr; 420(3):644-50. PubMed ID: 22450313
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous involvement in multiple myeloma and bortezomib.
Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
[No Abstract] [Full Text] [Related]
17. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
18. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
20. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
